Comparative Profiling of TG2 and Its Effectors in Human Relapsing Remitting and Progressive Multiple Sclerosis

Comparative Profiling of TG2 and Its Effectors in Human Relapsing Remitting and Progressive Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic CNS autoimmune disease characterized by immune-mediated demyelination, axon loss, and disability. Dysregulation of transglutaminase-2 (TG2) has been implicated in disease initiation and progression. Herein, TG2 expression in post-mortem human brain tissue from Re...

Full description

Bibliographic Details
Main Authors:	Damien D. Pearse, Andrew B. Hefley, Alejo A. Morales, Mousumi Ghosh
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Biomedicines
Subjects:	Multiple Sclerosis Relapsing-Remitting Multiple Sclerosis Progressive Multiple Sclerosis transglutaminase-2 blood–brain barrier disruption perivascular lesion
Online Access:	https://www.mdpi.com/2227-9059/10/6/1241

Similar Items

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
by: Martha Rocio Hernández-Preciado, et al.
Published: (2022-06-01)

Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary‐progressive and relapsing‐remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases
by: Priyadarshi Prajjwal, et al.
Published: (2023-07-01)

Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression
by: Laura Barcutean, et al.
Published: (2024-03-01)

Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis
by: Smaranda Maier, et al.
Published: (2023-02-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
by: Sylwia Pietrasik, et al.
Published: (2021-11-01)

Clinical markers for unfavorable course of multiple sclerosis
by: Mariya S. Matrosova, et al.
Published: (2023-09-01)

Vitamin D intoxication in a patient with relapsing-remitting multiple sclerosis – case report
by: Ioana Cociasu, et al.
Published: (2015-09-01)

Physical activity is related to disease severity and fatigue, but not to relapse rate in persons with relapsing remitting multiple sclerosis – a self-reported questionnaire based study
by: Marit L. Schlagheck, et al.
Published: (2023-07-01)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
by: Ricardo Ginestal, et al.
Published: (2023-01-01)

Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing–Remitting Multiple Sclerosis
by: Anna Bizoń, et al.
Published: (2023-08-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
by: Flavia Salvaterra Cusin, et al.
Published: (2022-10-01)

Identification of Key Ferroptosis-Related Genes in the Peripheral Blood of Patients with Relapsing-Remitting Multiple Sclerosis and Its Diagnostic Value
by: Xi Song, et al.
Published: (2023-03-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
by: Halil Önder
Published: (2019-06-01)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
by: Sainz de la Maza S, et al.
Published: (2023-06-01)

Comparing power and activity of lower body muscles in two types of multiple sclerosis patients and healthy individuals
by: Talebi V, et al.
Published: (2020-05-01)

The Use of Nitrosative Stress Molecules as Potential Diagnostic Biomarkers in Multiple Sclerosis
by: Saskia Räuber, et al.
Published: (2024-01-01)

Sex, aging and immunity in multiple sclerosis and experimental autoimmune encephalomyelitis: An intriguing interaction
by: Marina Boziki, et al.
Published: (2023-01-01)

Effect of disease duration on personality type in multiple sclerosis patients and healthy individual
by: Sahar Vesal, et al.
Published: (2016-01-01)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
by: Mansour A. Alharbi, et al.
Published: (2023-05-01)

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
by: Francisco Gascón-Giménez, et al.
Published: (2023-03-01)

Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report
by: Marios Lemonaris, et al.
Published: (2024-01-01)

Demographic and disease‐related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis
by: Kamila Zondra Revendova, et al.
Published: (2023-01-01)

Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia
by: Ana Jerković, et al.
Published: (2022-07-01)

High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trialResearch in context
by: Sandra D. Cassard, et al.
Published: (2023-05-01)

Changes in retinal structures as markers of multiple sclerosis progression
by: M. O. Poplyak, et al.
Published: (2021-12-01)

Evaluation of Diffusion Tensor Imaging Findings in Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis Patients
by: Özkan Alataş, et al.
Published: (2023-04-01)

The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model
by: Gabriele Di Sante, et al.
Published: (2020-03-01)

Linear Modeling of Multiple Sclerosis and Its Subgroubs
by: Yeliz Karaca, et al.
Published: (2015-03-01)

Exploring humanistic burden of fatigue in adults with multiple sclerosis: an analysis of US National Health and Wellness Survey data
by: Hoa H. Le, et al.
Published: (2024-02-01)

Predominant domains and associated demographic and clinical characteristics in multiple sclerosis-related cognitive impairment in mildly disabled patients
by: Mahnaz Talebi, et al.
Published: (2022-05-01)

Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
by: Takahiko Saida, et al.
Published: (2023-08-01)

Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review
by: D. L. Klabukova, et al.
Published: (2018-11-01)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
by: Daniel Kantor, et al.
Published: (2023-03-01)

Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase
by: Zbyšek Pavelek, et al.
Published: (2020-05-01)

Longitudinal cortex reorganization and white matter tracts structural changes analysis in relapsing-remitting multiple sclerosis patients with hand palsy
by: S. N. Kulikova, et al.
Published: (2017-02-01)

Progression of Relapsing-Remitting Multiple Sclerosis despite the new era of treatments
by: Gutemberg Augusto Cruz dos Santos, et al.
Published: (2022-12-01)

Fingolimod (FTY720) Tedavisinin Relapsing-Remitting Multipl Skleroz Hastalarında Karaciğer Enzim Düzeylerine Etkisi
by: Duygu Tap, et al.
Published: (2020-12-01)